TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17676393
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg q.d.) plus placebo
Study: 12538214
Drug: Sameridine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sameridine (25 mg)
Study: 12538214
Drug: Bupivacaine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (15 mg)
Study: 8712322
Drug: Tropisetron 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 0.1 mg.kg‐1
Study: 1505606
Drug: verapamil 40
Normalized name: verapamil 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 40 mg every 8 h
Study: 1505606
Drug: verapamil 80
Normalized name: verapamil 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 80 mg every 8 h
Study: 1505606
Drug: verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 120 mg every 8 h
Study: 6832463
Drug: Dothiepin three
Normalized name: dothiepin
DrugBank: Dosulepin (DB09167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin three times a day (75 mg to 225 mg per day)
Study: 6832463
Drug: Dothiepin as
Normalized name: dothiepin
DrugBank: Dosulepin (DB09167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin as a single night-time dose (75 mg to 225 mg per day)
Study: 6832463
Drug: Dothiepin as
Normalized name: dothiepin
DrugBank: Dosulepin (DB09167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin as a single night-time dose
Study: 27842191
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg ranibizumab (Lucentis) in the sustained group
Study: 27842191
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg ranibizumab (Lucentis) in the PRN group
Study: 27842191
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with 0.3 mg ranibizumab (Lucentis)
Study: 27842191
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg ranibizumab (Lucentis) overall
Study: 17250746
Drug: 1 l/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 l/min oxygen in air (50% oxygen)
Study: 17250746
Drug: 2 l/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 l/min oxygen in air (50% oxygen)
Study: 17250746
Drug: 3 l/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 l/min (33% oxygen)
Study: 17250746
Drug: 3 l/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 l/min oxygen in nitrous oxide (33% oxygen)
Study: 17250746
Drug: Lowest oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest oxygen in air group (1 l/min)
Study: 15839740
Drug: co-artemether (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-artemether (six doses)
Study: 15839740
Drug: CQ/SP (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQ/SP (three doses of CQ and one dose of SP)
Study: 10453586
Drug: Electro-acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture and routine treatments (group 1, n = 31)
Study: 10453586
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (group 2, n = 33)
Study: 30919411
Drug: Cardiovascular screening
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiovascular screening examination using low-dose non-contrast CT, ankle and brachial BP measurements, and blood tests
Study: 25154849
Drug: Continuous paravertebral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous paravertebral nerve block (PVB) with 0.2% ropivacaine 250 ml in continuous infusion, assisted with intravenous morphine patient‐controlled analgesia.
Study: 25154849
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CEA) with 0.2% ropivacaine 250 ml in continuous infusion, assisted with intravenous morphine patient‐controlled analgesia.
Study: 17215846
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (lansoprazole 30 mg b.i.d., clarithromycin 400 mg b.i.d., amoxicillin 750 mg b.i.d. for 1 week)
Study: 12387471
Drug: Postnatal support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postnatal support group run weekly with a facilitator, starting two weeks postpartum.
Study: 7707448
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg mebendazole
Study: 2616586
Drug: Isoxicam (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoxicam (200 mg/24 h)
Study: 2616586
Drug: Indomethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (150 mg/24 h)
Study: 467194
Drug: Lateral subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral subcutaneous sphincterotomy (LSS) during local anesthesia
Study: 467194
Drug: Lateral subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral subcutaneous sphincterotomy (LSS)
Study: 467194
Drug: Manual dilatation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual dilatation of the anus (MDA) and Lateral subcutaneous sphincterotomy (LSS)
Study: 31213097
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost therapy
Study: 28560780
Drug: Natural agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural agents (propolis, aloe vera, calendula, chamomile)
Study: 22835005
Drug: Comprehensive nonsurgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive nonsurgical periodontal therapy before 24 gestational weeks (n = 30)
Study: 22754923
Drug: O2 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: O2 administered via nasal cannula for the first 10 minutes, followed by 10 minutes with O2 bar on without O2.
Study: 22754923
Drug: O2 bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: O2 bar remained on without O2 being administered for the first 10 minutes, followed by 10 minutes of O2 via nasal cannula.
Study: 19309389
Drug: Step-up therapy
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up therapy (n = 293)
Study: 19309389
Drug: Step-down therapy
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down therapy (n = 226)
Study: 17365932
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg once daily + Losartan 50 mg
Study: 17365932
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg once daily + Ramipril 5 mg
Study: 17365932
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg once daily + Carvedilol 25 mg
Study: 15096406
Drug: Rasagiline, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline, 2 mg/d for 1 year
Study: 15096406
Drug: Rasagiline, 1
Normalized name: Rasagiline, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline, 1 mg/d for 1 year
Study: 15096406
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 6 months followed by rasagiline, 2 mg/d for 6 months
Study: 11549204
Drug: Imidapril 10
Normalized name: imidapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril 10 mg combined with Nilvadipine
Study: 11549204
Drug: Imidapril 10
Normalized name: imidapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril 10 mg combined with Hydrochlorothiazide
Study: 11549204
Drug: Imidapril 10
Normalized name: imidapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril 10 mg combined with Bisoprolol
Study: 11549204
Drug: Imidapril 10
Normalized name: imidapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril 10 mg combined with Hydrochlorothiazide, Bisoprolol, or Nilvadipine
Study: 9041068
Drug: Hospital-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-treatment group (H)
Study: 25675063
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 5 mL (Group A)
Study: 25675063
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 4.5 mL + 20 mg of triamcinolone 0.5 mL (Group B)
Study: 25675063
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 4 mL + 40 mg of triamcinolone 1 mL (Group C)
Study: 22961576
Drug: LOGIC-Insulin algorithm-guided
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LOGIC-Insulin algorithm-guided glycemic control (LOGIC-C)
Study: 20491750
Drug: Paracetamol 4
Normalized name: Paracetamol 48.2 mg/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 4 g/day for 5 days
Study: 18440447
Drug: Methylnaltrexone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylnaltrexone (all doses)
Study: 12618276
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg per day)
Study: 8756362
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose preoperative radiation ( > or = 45 Gray [Gy]) followed by surgical resection (Group A)
Study: 3886564
Drug: Cefotiam 1
Normalized name: cefotiam
DrugBank: Cefotiam (DB00229)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotiam 1 g b.i.d. for 7 to 14 days
Study: 3886564
Drug: Cefamandole 1
Normalized name: cefamandole 1 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole 1 g t.i.d. for 7 to 14 days
Study: 30376084
Drug: Oral polio
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polio vaccine (OPV) administered during national health week (NHW) to 1 child under 5 in vaccinated households.
Study: 27323337
Drug: Ranolazine (R)
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine (R) at a dose of 500 mg/bid
Study: 27323337
Drug: Beta-blockers or
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers or calcium-channel blockers (control)
Study: 24558028
Drug: Complex lymphedema
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex lymphedema therapy (CLT)
Study: 22154315
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in patients <75 years old
Study: 22154315
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in patients ≥75 years old
Study: 17594783
Drug: L-dopa therapy
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa therapy in patients with PD
Study: 17594783
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with PD not receiving L-dopa
Study: 12153376
Drug: Enoxaparin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1.5 mg/kg once a day)
Study: 7033157
Drug: Cefamandole 1
Normalized name: cefamandole 1 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole 1 gm IM every 6 hrs for 8 doses and Tobramycin 1 mg/kg IM for 1 dose, starting 2 hrs prior to surgery
Study: 26615912
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with 25-hydroxy vitamin D concentration <10 ng/ml
Study: 23183541
Drug: Accelerated up-dosing
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated up-dosing regimen (0.1-0.3-0.5 ml in weekly intervals)
Study: 23183541
Drug: Conventional up-dosing
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional up-dosing regimen (0.05-0.1-0.2-0.3-0.4-0.5 ml in weekly intervals)
Study: 21711202
Drug: Yoga Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga Therapy program (YT)
Study: 16922792
Drug: Amphotericin-B-lipid-complex (ABLC)
Normalized name: AMPHOTERICIN B LIPID COMPLEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphotericin-B-lipid-complex (ABLC) prophylaxis, 4 mg/kg, twice weekly starting on day +30 for patients on prednisone ≥30 mg/day.
Study: 16922792
Drug: Fluconazole or
Normalized name: fluconazole Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole or itraconazole (200-400 mg/day) during neutropenic episode, continued for patients on lower steroid doses.
Study: 15195060
Drug: CIP/DEX (ciprofloxacin/dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIP/DEX (ciprofloxacin/dexamethasone otic suspension) 4 drops twice daily for 7 days
Study: 15195060
Drug: OFL (ofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFL (ofloxacin otic solution) 5 drops twice daily for 10 days
Study: 9723629
Drug: Fixed minidose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed minidose warfarin (1.25 mg/day)
Study: 9723629
Drug: Standard adjusted-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adjusted-dose warfarin (INR between 2.0 and 3.0)
Study: 8210254
Drug: CPT-11 (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 (irinotecan hydrochloride) administered as 100 mg/m2 weekly intravenous infusion or 150 mg/m2 fortnightly
Study: 2691484
Drug: Amoxycillin/clavulanate iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate iv (single prophylactic dose)
Study: 5313064
Drug: Pyrimethamine 2
Normalized name: pyrimethamine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine 2 mg with sulfadoxine 40 mg, fortnightly
Study: 5313064
Drug: Pyrimethamine alone
Normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrimethamine alone at the recommended dose
Study: 29228000
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum ECGC 13110402 (2x10^9 CFU twice daily)
Study: 21270121
Drug: Adjuvanted vaccines
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted vaccines (Pandemrix, Focetria, FluvalP)
Study: 21270121
Drug: Non-adjuvanted vaccines
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted vaccines (Celvapan)
Study: 19944317
Drug: Edaravone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone (30 mg intravenously infused just before reperfusion)
Study: 9249209
Drug: i.v. chloramphenicol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. chloramphenicol 30 mg/kg
Study: 9249209
Drug: i.m. chloramphenicol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. chloramphenicol 30 mg/kg
Study: 8497817
Drug: Frusemide (33.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (33.2 mg)
Study: 25703647
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of ACT1 (alpha connexin carboxy-terminal)
Study: 25703647
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of ACT1
Study: 21443516
Drug: NVP 400
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP 400 mg QD
Study: 21443516
Drug: NVP 200
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP 200 mg BID
Study: 18502299
Drug: Oral hypoglycaemic
Normalized name: Biguanide oral hypoglycaemic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycaemic agents
Study: 8680886
Drug: Acemannan (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acemannan (400 mg orally four times daily)
Study: 1880218
Drug: Spirapril 12
Normalized name: spirapril 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 12 mg to 48 mg once daily
Study: 7040186
Drug: Betahistine dihydrochloride
Normalized name: Betahistine Dihydrochloride
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine dihydrochloride (3 X 8 mg)
Study: 7040186
Drug: Hydrochlorothiazide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (3 X 25 mg)
Study: 30321272
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg capsule containing 100 mg seaweed (poly)phenol and 300 mg maltodextrin
Study: 30321272
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg maltodextrin placebo control capsule
Study: 26968850
Drug: Mindfulness meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness meditation and cognitive behavioral therapy (CBT) intervention
Study: 9312196
Drug: Intermittent slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent slow-release sodium fluoride (SRNaF, 25 mg B.I.D.) plus calcium citrate (400 mg Ca B.I.D.)
Study: 9312196
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus calcium citrate (400 mg Ca B.I.D.)
Study: 8369129
Drug: customary treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: customary treatments
Study: 3749390
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (0.15 mg/kg)
Study: 31738192
Drug: Telephone-delivered exercise
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered exercise therapy (n = 10)
Study: 31738192
Drug: In-person delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person delivered exercise therapy (n = 10)
Study: 26370061
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) 50,000 U administered 30 min prior to CA
Study: 26370061
Drug: Cystatin C
Normalized name: Cystatin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystatin C (CC)
Study: 23586514
Drug: Pulverized lanthanum
Normalized name: lanthanum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulverized lanthanum carbonate (LC) chewable preparation
Study: 20525842
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) treatment for 6 months
Study: 14529098
Drug: HFA-albuterol delivered
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-albuterol delivered via Autohaler (1, 2, or 4 puffs)
Study: 14529098
Drug: HFA-albuterol delivered
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-albuterol delivered via P&B (1 or 2 puffs)
Study: 11127933
Drug: Anticytokine antibodies,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticytokine antibodies, cytokines or cytokine-modifying agents
Study: 8803588
Drug: Captopril 6.25
Normalized name: captopril 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 6.25 mg orally (first dose) 2-4 hours after starting thrombolysis, increased up to 25 mg every 8 hours.
Study: 1379009
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no volume therapy)
Study: 24446955
Drug: Group psychoeducation
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychoeducation sessions (3 successive monthly sessions)
Study: 16801644
Drug: Generic antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic antioxidant treatment (n = 17)
Study: 6383833
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg t.i.d. after six months treatment
Study: 24740137
Drug: Dexibuprofen 400
Normalized name: Dexibuprofen 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexibuprofen 400 mg powder for oral suspension (daily dose 800 mg)
Study: 24740137
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg powder for oral suspension (daily dose 1,600 mg)
Study: 24740137
Drug: Dexibuprofen and
Normalized name: hydrocodone and ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexibuprofen and Ibuprofen
Study: 12271721
Drug: Children's live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children's live influenza vaccine (LIVI)
Study: 12271721
Drug: Adult live
Normalized name: Heterologous human adult liver derived progenitor cells
DrugBank: Heterologous human adult liver derived progenitor cells (DB17695)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult live influenza vaccine (LIVII)
Study: 12271721
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (LIVI and LIVII)
Study: 7769082
Drug: Misoprostol (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (after mifepristone pre-treatment)
Study: 2186323
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acylaminopenicillin plus aminoglycoside
Study: 2186323
Drug: Double beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double beta lactam therapy
Study: 31519284
Drug: WEACURE® (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: WEACURE® (500 mg of Jadwar root powder)
Study: 28424257
Drug: Animal-source food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-source food (ASF) supplement (mean: 144 kcal, 8.9 mg Fe, 2.7 mg Zn, 1050 μg retinoic acid equivalent vitamin A, and 5.5 μg vitamin B-12)
Study: 28424257
Drug: Control snack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control snack (mean: 150 kcal, 2.0 mg Fe, 0.9 mg Zn, 0 μg retinoic acid equivalent vitamin A, and 0 μg vitamin B-12)
Study: 28424257
Drug: Animal-source food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-source food (ASF) supplement
Study: 24809429
Drug: Oral Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nutritional Supplementation (ONS) - 2 servings (460 mL) daily providing 432 kcal, 16 g protein, and 28 micronutrients for 12 weeks
Study: 24809429
Drug: Oral Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nutritional Supplementation (ONS)